Who makes triple attack therapy?

triple attack therapy is developed by Kasr El Aini Hospital.

What development phase is triple attack therapy in?

triple attack therapy is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

triple attack therapy

Kasr El Aini Hospital · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	triple attack therapy
Also known as	KLACID XL 500 mg, HEALSEC 20 mg, Flagyly 500 mg
Sponsor	Kasr El Aini Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma (PHASE2)
Treatment of Multiple Attacks of Acute Migraine (0462-025) (PHASE3)
Safety and Efficacy of Left Atrial Appendage Closure Versus Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Due to Complex Coronary Artery Disease (PHASE4)
Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy? (PHASE4)
Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

triple attack therapy CI brief — competitive landscape report
triple attack therapy updates RSS · CI watch RSS
Kasr El Aini Hospital portfolio CI